Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
New developments of aminobisphosphonates: the double face of Janus.
Santini D, Galluzzo S, Vincenzi B, Schiavon G, Fratto E, Pantano F, Tonini G. Santini D, et al. Among authors: galluzzo s. Ann Oncol. 2007 Jun;18 Suppl 6:vi164-7. doi: 10.1093/annonc/mdm249. Ann Oncol. 2007. PMID: 17591815 Free article. Review.
Denosumab: the era of targeted therapies in bone metastatic diseases.
Santini D, Fratto ME, Vincenzi B, Napoli N, Galluzzo S, Tantardini M, Abbruzzese A, Caraglia M, Tonini G. Santini D, et al. Among authors: galluzzo s. Curr Cancer Drug Targets. 2009 Nov;9(7):834-42. doi: 10.2174/156800909789760375. Curr Cancer Drug Targets. 2009. PMID: 20025571 Review.
New molecular targets in bone metastases.
Santini D, Galluzzo S, Zoccoli A, Pantano F, Fratto ME, Vincenzi B, Lombardi L, Gucciardino C, Silvestris N, Riva E, Rizzo S, Russo A, Maiello E, Colucci G, Tonini G. Santini D, et al. Among authors: galluzzo s. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S6-S10. doi: 10.1016/S0305-7372(10)70013-X. Cancer Treat Rev. 2010. PMID: 21129612 Review.
Zoledronic acid in the management of metastatic bone disease.
Santini D, Fratto ME, Vincenzi B, Galluzzo S, Tonini G. Santini D, et al. Among authors: galluzzo s. Expert Opin Biol Ther. 2006 Dec;6(12):1333-48. doi: 10.1517/14712598.6.12.1333. Expert Opin Biol Ther. 2006. PMID: 17223741 Review.
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G. Santini D, et al. Among authors: galluzzo s. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4482-6. doi: 10.1158/1078-0432.CCR-07-0551. Clin Cancer Res. 2007. PMID: 17671133
Are bisphosphonates the suitable anticancer drugs for the elderly?
Santini D, Fratto ME, Galluzzo S, Vincenzi B, Tonini G. Santini D, et al. Among authors: galluzzo s. Crit Rev Oncol Hematol. 2009 Jan;69(1):83-94. doi: 10.1016/j.critrevonc.2008.07.008. Epub 2008 Aug 8. Crit Rev Oncol Hematol. 2009. PMID: 18692400 Review.
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.
Vincenzi B, Galluzzo S, Santini D, Rocci L, Loupakis F, Correale P, Addeo R, Zoccoli A, Napolitano A, Graziano F, Ruzzo A, Falcone A, Francini G, Dicuonzo G, Tonini G. Vincenzi B, et al. Among authors: galluzzo s. Ann Oncol. 2011 May;22(5):1141-1146. doi: 10.1093/annonc/mdq550. Epub 2010 Nov 29. Ann Oncol. 2011. PMID: 21115601 Free article.
In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients.
Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, Turchi F, Piacentini P, Rocci L, Manavalan JS, Tonini G, Poccia F. Santini D, et al. Among authors: galluzzo s. Cancer Immunol Immunother. 2009 Jan;58(1):31-8. doi: 10.1007/s00262-008-0521-6. Epub 2008 May 6. Cancer Immunol Immunother. 2009. PMID: 18458903 Free PMC article. Clinical Trial.
59 results